Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

Posts tagged bictegravir
What is Gilead's exposure from GSK's patent lawsuit against Biktarvy®, Gilead's new integrase inhibitor HIV therapy?

Gilead’s new HIV drug, Biktarvy®, has received FDA approval.  Almost immediately, Gilead was hit with a patent-infringement lawsuit by ViiV Healthcare, which is owned by GSK, along with Pfizer and Shionogi.  What is Gilead’s exposure?

Read More